IL17A and metabolic dysfunction-associated steatotic liver disease: Furthermore, obesity-induced IL-17 is considered central to the development and progression of non-alcoholic fatty liver disease to steatohepatitis [220]; increased peripheral IL-17 levels are associated with early atherosclerosis in obese patients [221,222].